5 Best Psychedelic Stocks to Buy in 2026

3. AtaiBeckley Inc (NASDAQ:ATAI)

Number of Hedge Fund Holders: 23

Average Upside Potential: 292.60%

AtaiBeckley Inc (NASDAQ:ATAI) is among the best psychedelic stocks to buy in 2026. On March 17, AtaiBeckley Inc (NASDAQ:ATAI) announced the publication in the Journal of Psychopharmacology of the Phase 2a study results for its flagship psychedelic drug candidate BPL-003. AtaiBeckley is developing BPL-003, which comes in the form of a nasal spray, as a treatment for treatment-resistant depression.

In that study, BPL-003 was evaluated in patients with moderate-to-severe treatment-resistant depression who were not on antidepressants. The study turned positive results on safety and efficacy.

With that, BPL-003 is advancing to Phase 3 trials. AtaiBeckley announced on March 10 that it plans to launch two parallel Phase 3 studies of BPL-003 in Q2 2026. The Phase 3 trials announcement followed a meeting with the FDA, with the company saying that the regulator indicated support for the Phase 3 program and provided constructive feedback.

On March 7, Bloomberg reported that AtaiBeckley was seeking a deal for BPL-003, which could be a sale or partnership. An outright sale of BPL-003 could fetch more than $2 billion for the company, while a partnership would involve sharing responsibilities and profit, according to the report.

New York-headquartered AtaiBeckley Inc (NASDAQ:ATAI) a clinical-stage biopharmaceutical company focused on developing mental health treatments. The company has multiple drug candidates in the pipeline, including BPL-003, which is aimed at people with treatment-resistant depression.